Your Feedback Can Help ensure a new treatment option for advanced Basal Cell Carcinoma (BCC) is available in Canada.
Take our 15-20 minute survey and get a chance to win 1 of 3 $25 Starbucks gift cards
Melanoma Network of Canada is providing a submission to aid in the process for determining provincial listing and coverage of cemiplimab (Libtayo) – an anti-pd1 immunotherapy indicated for the treatment of patients with locally advanced basal cell carcinoma (laBCC) or metastatic basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate.
Your input in our 15-20 minute survey will help us prepare a group submission to the pan-Canadian Oncology Drug Review (pCODR) on the experiences and opinions of patients and their caregivers. As many of you already know, effective treatment therapies for advanced or metastatic basal cell carcinoma are very limited, this new therapy holds significant promise for survival.
All patients – no matter what stage – and caregivers can participate in our survey.
Participation in this survey is voluntary. If you choose to begin the survey, you may withdraw at any time. Your responses will be anonymous and confidential.
To participate in this survey, please click the link below. The survey will remain open for completion until midnight (EST) on September 8th, 2021.
QUESTIONS?
If you have any questions, you may contact Melanoma Network of Canada by telephone at 1.877.560.8035 or email acyr@melanomanetwork.ca
About (pCODR) The Pan Canadian Oncology Drug ReviewThe Pan Canadian Oncology Drug Review, (pCODR) is an evidence-based, cancer drug review process in Canada. The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada’s provinces and territories (except Quebec) in guiding their drug funding decisions. Under the pCODR process, detailed assessments are conducted by a pan-Canadian expert review committee, with opportunities for input by patient advocacy groups, the pharmaceutical industry, clinician-based tumour groups, and the provincial advisory group.
